Naturalendo Tech Past Earnings Performance
Past criteria checks 0/6
Naturalendo Tech has been growing earnings at an average annual rate of 22.5%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 17.4% per year.
Key information
22.5%
Earnings growth rate
36.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 17.4% |
| Return on equity | -19.2% |
| Net Margin | -22.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Naturalendo Tech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 21,843 | -4,921 | 9,481 | 2,193 |
| 31 Mar 24 | 20,319 | -4,257 | 8,298 | 2,119 |
| 31 Dec 23 | 18,790 | -4,368 | 7,580 | 2,196 |
| 30 Sep 23 | 17,093 | -6,142 | 6,958 | 2,240 |
| 30 Jun 23 | 15,546 | -6,674 | 6,833 | 2,183 |
| 31 Mar 23 | 15,038 | -9,404 | 7,339 | 2,149 |
| 31 Dec 22 | 13,951 | -10,084 | 7,632 | 1,984 |
| 30 Sep 22 | 10,781 | -10,097 | 8,336 | 1,848 |
| 30 Jun 22 | 10,807 | -10,334 | 8,850 | 1,866 |
| 31 Mar 22 | 12,218 | -6,862 | 8,529 | 1,784 |
| 31 Dec 21 | 14,696 | -5,079 | 9,063 | 1,653 |
| 30 Sep 21 | 17,486 | -2,601 | 7,859 | 1,601 |
| 30 Jun 21 | 17,974 | -378 | 7,123 | 1,458 |
| 31 Mar 21 | 15,646 | -1,493 | 6,613 | 1,379 |
| 31 Dec 20 | 13,247 | -1,673 | 5,171 | 1,478 |
| 30 Sep 20 | 9,655 | -5,953 | 5,062 | 1,805 |
| 30 Jun 20 | 8,439 | -10,320 | 5,248 | 2,039 |
| 31 Mar 20 | 7,503 | -11,558 | 4,356 | 2,162 |
| 31 Dec 19 | 6,580 | -13,413 | 5,173 | 2,176 |
| 30 Sep 19 | 7,663 | -21,942 | 6,188 | 2,135 |
| 30 Jun 19 | 8,311 | -20,607 | 7,256 | 2,150 |
| 31 Mar 19 | 9,116 | -19,243 | 7,566 | 2,331 |
| 31 Dec 18 | 8,928 | -19,500 | 7,314 | 2,386 |
| 30 Sep 18 | 8,931 | -6,446 | 6,352 | 2,091 |
| 30 Jun 18 | 9,663 | -5,711 | 5,261 | 1,873 |
| 31 Mar 18 | 9,072 | -8,666 | 6,270 | 1,728 |
| 31 Dec 17 | 9,239 | -8,861 | 6,544 | 1,612 |
| 30 Sep 17 | 9,145 | -14,216 | 10,177 | 1,568 |
| 30 Jun 17 | 6,669 | -14,325 | 9,730 | 1,542 |
| 31 Mar 17 | 6,905 | -15,145 | 10,829 | 1,420 |
| 31 Dec 16 | 6,556 | -13,177 | 9,705 | 1,434 |
| 30 Sep 16 | 5,103 | -8,721 | 5,590 | 1,541 |
| 30 Jun 16 | 4,676 | -8,857 | 8,352 | 1,743 |
| 31 Mar 16 | 9,156 | -21,023 | 21,997 | 2,132 |
| 31 Dec 15 | 44,506 | -15,516 | 38,534 | 2,298 |
| 30 Sep 15 | 72,019 | -9,673 | 51,488 | 2,377 |
| 30 Jun 15 | 110,388 | -1,491 | 65,789 | 2,386 |
| 31 Mar 15 | 136,235 | 20,464 | 63,780 | 2,208 |
| 31 Dec 14 | 124,067 | 20,761 | 55,852 | 2,022 |
Quality Earnings: A168330 is currently unprofitable.
Growing Profit Margin: A168330 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A168330 is unprofitable, but has reduced losses over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare A168330's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A168330 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A168330 has a negative Return on Equity (-19.16%), as it is currently unprofitable.